![conference banner](/images/conference-banner.jpeg)
摘要
阿尔茨海默氏症(AD)是一种慢性神经退行性脑疾病,其特征是老年人的记忆障碍、痴呆和氧化应激。目前,市场上只有几种副作用。因此,为了开发具有对疾病有保护作用的新药,研究正转向鉴定植物产品作为一种补救药物。具有抗炎活性的天然化合物可能成为开发有效治疗策略的好候选药物。植物化学物质,包括姜黄素、白藜芦醇、槲皮素、胡培嗪a、迷迭香酸、染料木素、卵波瓦醇和奥氧维他醇,被报道为治疗AD的分子。一些生物碱,如甘兰他胺、冬冬苷、B、四山嘌呤、小檗碱和阿那他滨,已在体内AD模型和体内均显示出抗炎作用。总之,来自植物的天然产物是治疗AD的有趣的候选药物。本综述强调了天然产物中的特定化合物及其合成衍生物抵消中枢神经系统中AD的潜力。
关键词: 淀粉样前体蛋白黄酮类,阿尔茨海默病,BACE-1,小胶质细胞,天然产物,植物化学物质。
Current Medicinal Chemistry
Title:Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Volume: 28 Issue: 23
关键词: 淀粉样前体蛋白黄酮类,阿尔茨海默病,BACE-1,小胶质细胞,天然产物,植物化学物质。
摘要: Alzheimer's disease (AD) is a chronic neurodegenerative brain disorder characterized by memory impairment, dementia, and oxidative stress in elderly people. Currently, only a few drugs are available in the market with various adverse effects. Therefore, to develop new drugs with protective action against the disease, research is turning to the identification of plant products as a remedy. Natural compounds with anti-inflammatory activity could be good candidates for developing effective therapeutic strategies. Phytochemicals, including Curcumin, Resveratrol, Quercetin, Huperzine-A, Rosmarinic acid, genistein, obovatol, and Oxyresvertarol, were reported molecules for the treatment of AD. Several alkaloids, such as galantamine, oridonin, glaucocalyxin B, tetrandrine, berberine and anatabine, have been shown anti-inflammatory effects in AD models in vitro as well as in-vivo. In conclusion, natural products from plants represent interesting candidates for the treatment of AD. This review highlights the potential of specific compounds from natural products along with their synthetic derivatives to counteract AD in the CNS.
Export Options
About this article
Cite this article as:
Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease, Current Medicinal Chemistry 2021; 28 (23) . https://dx.doi.org/10.2174/0929867327666200730213215
DOI https://dx.doi.org/10.2174/0929867327666200730213215 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volum 2
Current Diabetes Reviews Advances in Tissue and Organ Replacement
Current Stem Cell Research & Therapy Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Bronchoalveolar Lavage in Systemic Sclerosis Patients: A Systematic Review
Current Rheumatology Reviews Molecular Targets in Osteoarthritis: Metalloproteinases and Their Inhibitors
Current Drug Targets Dietary Approaches and Alternative Therapies for Rheumatoid Arthritis
Current Nutrition & Food Science Primary Sjögren’s Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Microbiome Medicine: Microbiota in Development and Management of Cardiovascular Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Protective Effects of Terpenes on the Cardiovascular System: Current Advances and Future Perspectives
Current Medicinal Chemistry Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets Nanoparticle-based Diagnostic Imaging of Inflammation in Rheumatic Disease
Current Rheumatology Reviews The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Interleukin-6 Therapy for Crohns Disease
Current Pharmaceutical Design Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design